my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
22-03-2011: Hundreds of Australian patients are set to trial a new oral vaccine designed to help people plagued by chronic respiratory infections, predominantly during winter.
Scientists at Hunter Immunology have developed a treatment for Chronic Obstructive Pulmonary Disorder, or COPD, which is being trialled on up to 340 patients at major hospitals around the country.
Recruitment is now underway at 23 sites, including The Austin Hospital, The Alfred and the Royal Melbourne in Victoria, St Vincents Hospital and the Prince of Wales Hospitals in Sydney and both Royal Brisbane and Royal Perth Hospitals.
The drug HI 164OV is taken orally and works by stimulating the immune system to alleviate the flare ups commonly occurring in patients with moderate to severe disease.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Probiomics Limited has confirmed its name change to Bioxyne following its successful reverse takeover by Hunter Immunology. Managing Director and Chief Executive Officer, David Radford, said the name change signalled a step towards positioning the business for future growth in Australia and ... more
Merger of Probiomics and Hunter Immunology to Speed Development of Promising New Vaccine
Hunter Immunology recommended shareholders accept the takeover offer from listed biotech Probiomics. The Company’s four largest shareholders, respected funds manager Chris Cuffe, investment group Intersuisse Biosciences and co-founders Dr Philip Comans and Professor Robert Clancy, who toget ... more
Hunter Immunology starts national lung disease vaccine trial
Hundreds of Australian patients are set to trial a new oral vaccine designed to help people plagued by chronic respiratory infections, predominantly during winter.Scientists at Hunter Immunology have developed a treatment for Chronic Obstructive Pulmonary Disorder, or COPD, which is being t ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
